Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | MAP2 | P11137 | 1/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308341 | 0.91 | FNTA (0.46) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4311494 | 0.89 | ALDH1A1 (0.41) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4310553 | 0.88 | ALDH1A1 (0.40) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4304062 | 0.88 | FNTA (0.44) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4311458 | 0.87 | FNTA (0.44) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4308917 | 0.87 | ALDH1A1 (0.39) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4307434 | 0.87 | MLNR (0.39) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4303720 | 0.86 | FNTA (0.40) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL13881231 | 0.85 | ALDH1A1 (0.38) | ALDH1A1FNTAFNTBMLNRCYP3A4 | |
| SCHEMBL4305887 | 0.85 | MLNR (0.38) | ALDH1A1FNTAFNTBMAP2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | claimed |
| EP-1954276-A2 | INDOLE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061763-A2 | INDOLE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | ALDH1A1 3088/4885FNTA 4072/4885FNTB 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.